Published in Ann Oncol on June 01, 2007
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J (2010) 1.52
The Clinical Significance of Unknown Sequence Variants in BRCA Genes. Cancers (Basel) (2010) 0.88
Haplotype analysis of BRCA1 intragenic markers in Iranian patients with familial breast and ovarian cancer. Int J Reprod Biomed (Yazd) (2016) 0.75
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol (2007) 3.26
The formation and maintenance of the definitive endoderm lineage in the mouse: involvement of HNF3/forkhead proteins. Development (1993) 3.22
Analysis and expression of a cloned pre-T cell receptor gene. Science (1994) 2.66
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology (2001) 2.53
Effect of a single, oral, high-dose vitamin D supplementation on endothelial function in patients with peripheral arterial disease: a randomised controlled pilot study. Eur J Vasc Endovasc Surg (2012) 2.12
The influence of a prolonged sitting position on the biochemical markers of coagulation activation in healthy subjects: evidence of reduced thrombin generation. J Thromb Haemost (2003) 1.96
Gene transfer: DNA microinjection compared with DNA transfection with a very high efficiency. Mol Cell Biol (1982) 1.94
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol (2002) 1.74
Radiofrequency thermal ablation of 69 lung neoplasms. J Chemother (2004) 1.58
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer (1994) 1.55
Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res (2001) 1.55
Genes from mycoparasitic fungi as a source for improving plant resistance to fungal pathogens. Proc Natl Acad Sci U S A (1998) 1.50
Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. J Intellect Disabil Res (2006) 1.48
Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol (1998) 1.47
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast (2010) 1.47
Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA. J Thromb Haemost (2009) 1.41
Standard vs. point-of-care measurement of fibrinogen: potential impact on clinical decisions. Minerva Anestesiol (2012) 1.40
Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. J Virol Methods (1998) 1.36
Breast cancer genome-wide association studies: there is strength in numbers. Oncogene (2011) 1.34
Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol (2006) 1.33
Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol (2001) 1.32
CD4+8- help prevents rapid deletion of CD8+ cells after a transient response to antigen. Eur J Immunol (1993) 1.29
Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J Clin Microbiol (2006) 1.29
Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol (2002) 1.29
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol (2007) 1.28
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol (2006) 1.18
Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res (1997) 1.17
Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology (2000) 1.17
The role of Aurora-A inhibitors in cancer therapy. Ann Oncol (2007) 1.16
Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer (1996) 1.15
Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J Biol Chem (1995) 1.14
Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res (1997) 1.11
Transforming potential of the insulin receptor substrate 1. Cell Growth Differ (1995) 1.11
Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene (2007) 1.11
Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes. J Hepatol (2001) 1.09
On the possible causes of the release of material absorbing at 260 m-mu by streptomycin treated E. coli cells (K 12 and B). J Antibiot (Tokyo) (1967) 1.08
Experimental study of patterns of brain distortion and ischemia produced by an intracranial mass. J Neurosurg (1968) 1.08
Association of insulin receptor substrate 1 with simian virus 40 large T antigen. Mol Cell Biol (1995) 1.07
In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis. Gastroenterology (1983) 1.06
[Release of nucleotides and integrity of the bacterial membrane (E. coli K 12)]. Antibiotica (1966) 1.06
Apoptosis: a relevant tool for anticancer therapy. Ann Oncol (2006) 1.05
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol (2005) 1.05
Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat Rev (2010) 1.05
IGF-I receptor-induced cell-cell adhesion of MCF-7 breast cancer cells requires the expression of junction protein ZO-1. J Biol Chem (2001) 1.04
The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin. Exp Cell Res (1999) 1.04
Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries. Int J Parasitol (2001) 1.04
Regulation of glomerular capillary pressure and filtration rate in young Kyoto hypertensive rats. Clin Sci (Lond) (1979) 1.04
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol (2006) 1.03
Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int J Cancer (1997) 1.03
Open-source, low-cost, high-reliability solutions for digital imaging systems: example of a "dicom router". Radiol Med (2007) 1.02
Laparoscopic drainage of liver abscess: case report and literature review. G Chir (2013) 1.02
Co-ordination of the expression of the protein tyrosine kinase p56(lck) with the pre-T cell receptor during thymocyte development. Eur J Immunol (2000) 1.01
Laparoscopic approach in abdominal emergencies: a 5-year experience at a single center. G Chir (2012) 1.01
Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res (1992) 1.01
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol (1988) 1.01
Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol (1996) 1.00
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer (2011) 1.00
Cloning and comparative analysis of the human pre-T-cell receptor alpha-chain gene. Proc Natl Acad Sci U S A (1995) 0.99
Long-acting thyroid stimulator and thyroid antibodies. Lancet (1966) 0.99
Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int J Cancer (1999) 0.98
Cardiac, skeletal, and ocular abnormalities in patients with Marfan's syndrome and in their relatives. Comparison with the cardiac abnormalities in patients with kyphoscoliosis. Br Heart J (1984) 0.98
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. Br J Cancer (2011) 0.98
Laparoscopy versus ultrasonography for the evaluation of Mullerian structures in children with complex disorders of sex development. Pediatr Surg Int (2012) 0.97
Laparoscopic, three-port and SILS cholecystectomy: a retrospective study. G Chir (2014) 0.96
Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev (2010) 0.96
miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene (2011) 0.96
RAG1, RAG2 and pre-T cell receptor alpha chain expression by adult human hepatic T cells: evidence for extrathymic T cell maturation. Eur J Immunol (1996) 0.96
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol (2007) 0.95
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol (2005) 0.95
New molecular targets in bone metastases. Cancer Treat Rev (2010) 0.95
In situ characterization of the cell-surface antigens of the mononuclear cell infiltrate and bile duct epithelium in primary biliary cirrhosis. Clin Immunol Immunopathol (1986) 0.95
DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol (2002) 0.94